{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fluorouracil", "query": { "intervention": "fluorouracil" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1674, "total_pages": 168, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fluorouracil&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T08:39:26.900Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00543842", "title": "Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2007-12", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-02-26", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00543842" }, { "nct_id": "NCT00591123", "title": "Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Adenocarcinoma of the Esophagus", "Metastatic Adenocarcinoma of the Esophagus", "Unresectable Adenocarcinoma of Gastric Cardia", "Metastatic Adenocarcinoma of Gastric Cardia" ], "interventions": [ { "name": "FOLFOX", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Oncology Research International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2007-12", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00591123" }, { "nct_id": "NCT00216086", "title": "Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "EUS", "type": "PROCEDURE" }, { "name": "Neoadjuvant Chemotherapy", "type": "DRUG" }, { "name": "Preoperative Radiation", "type": "PROCEDURE" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Adjuvant Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Gabi Chiorean, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2005-05", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 9, "location_summary": "Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more", "locations": [ { "city": "Elkhart", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216086" }, { "nct_id": "NCT03414983", "title": "An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2018-02-20", "completion_date": "2022-12-28", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414983" }, { "nct_id": "NCT00203905", "title": "A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil, Hydroxyurea-[FHX]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2004-01", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00203905" }, { "nct_id": "NCT02231723", "title": "A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "BBI608", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "MM-398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2014-08", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231723" }, { "nct_id": "NCT04753879", "title": "Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-09-29", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753879" }, { "nct_id": "NCT01102088", "title": "Simultaneous Integrated Boost (SIB) in Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2010-04", "completion_date": "2019-06-08", "has_results": false, "last_update_posted_date": "2020-05-22", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01102088" }, { "nct_id": "NCT06840886", "title": "A Study of PHST001 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Ovarian Cancer", "Endometrial Cancer", "Cholangiocarcinoma", "CNS Tumor" ], "interventions": [ { "name": "PHST001", "type": "BIOLOGICAL" }, { "name": "Chemotherapy per Standard of Care", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pheast Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2025-03-31", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 20, "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06840886" }, { "nct_id": "NCT00316420", "title": "Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Capecitabine (Xeloda)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Swedish Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2003-12", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2010-03-08", "last_synced_at": "2026-06-07T08:39:26.900Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316420" } ] }